A Multi-Center, phase 1/2 Trial of AlloNK® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

20260 citationsJournal Article

Authors

Good health and well-being

Published in: Transplantation and Cellular Therapy

Volume 32, Issue 2, pp. S372-S372

Field-Weighted Citation Impact: 0.00